What is the liraglutide peptide?
Liraglutide is a modified peptide analogue of human glucagon-like peptide-1 (GLP-1) and a GLP-1 receptor agonist. The name identifies a particular molecule. It does not, by itself, identify a complete medicinal product, an approved use or an independently verified research material.
The molecule's design and its clinical evidence answer different questions. Original structure–activity research around liraglutide examined how the fatty-acid component and connecting spacer affected receptor-related potency and prolonged action. Clinical studies then tested defined interventions in specific populations.
How is liraglutide related to human GLP-1?
The VICTOZA prescribing information describes an arginine substitution at position 34 and a C16 fatty acid attached through a glutamic-acid spacer at lysine 26. These modifications distinguish liraglutide from the native GLP-1 peptide.
The structure–activity paper is useful here because it investigated variations around the molecule rather than treating every GLP-1-related sequence as interchangeable. A similar family name does not remove the need to identify the actual analogue, side chain and material studied.
Scroll horizontally to read all columns.
| Question | Record to examine |
|---|---|
| Which molecule is it? | Sequence, substitutions and attached groups. |
| What does it do at a receptor? | Receptor-specific pharmacology and the assay conditions. |
| What clinical result was observed? | The trial's formulation, population, comparator and endpoint. |
| What does a medicine's label say? | The exact product and current jurisdiction-specific record. |
What does GLP-1 receptor activity explain?
The VICTOZA label describes GLP-1 receptor activation and glucose-dependent insulin secretion, together with effects on glucagon secretion and gastric emptying. These are pharmacological descriptions; they are not a complete clinical outcome or safety assessment.
Keep the level of evidence visible: a receptor assay, a hormone response and a trial endpoint are not the same measurement. The metabolic peptide pathway guide organizes related signaling families, while the endpoint guide explains how to read the clinical question.
What is the half-life of liraglutide?
The SAXENDA prescribing information reports an elimination half-life of approximately 13 hours following subcutaneous administration. Keep that formulation and measurement context attached to the number.
An elimination half-life describes declining drug exposure; it is not a storage-stability result for an unspecified preparation. It also differs from the radioactive half-life discussed in our PRRT half-life guide. A shared word does not make the underlying measurements interchangeable.
Which liraglutide studies answer which questions?
The following studies illustrate distinct populations and endpoints. They are selected examples, rather than an exhaustive review or a ranking of treatments.
Scroll horizontally to read all columns.
| Study | Population and comparison | Main question |
|---|---|---|
| SCALE Obesity and Prediabetes, 2015 | Adults without type 2 diabetes meeting the study's body-mass-index and related eligibility criteria; liraglutide versus placebo, with lifestyle counseling in both groups. | Body-weight change and weight-loss response over 56 weeks. |
| SCALE Diabetes, 2015 | Adults with overweight or obesity and type 2 diabetes; liraglutide groups versus placebo alongside diet and activity measures. | Weight-related outcomes in a population with diabetes. |
| LEADER, 2016 | People with type 2 diabetes and high cardiovascular risk; liraglutide versus placebo added to standard care. | A composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. |
The SCALE Obesity and Prediabetes publication reported greater weight reduction in the liraglutide group under its study conditions. Its result belongs to the assigned intervention and population, including the lifestyle component.
SCALE Diabetes supplies separate evidence in adults with type 2 diabetes. That difference matters when comparing findings: the diabetes and non-diabetes populations should not be pooled into a single undifferentiated promise.
LEADER reported fewer primary composite cardiovascular events with liraglutide than with placebo in its high-risk diabetes population. A composite result should not be described as proof that every individual component improved to the same extent, or as an estimate for every population.
Why Saxenda, Victoza and research material need separate records
Saxenda and Victoza both contain liraglutide, but their US prescribing information describes different indications and product-specific requirements. Use the exact product's current record for an eligibility, contraindication or safety question. The labels contain warnings and adverse-event information that a mechanism summary cannot replace.
Clinical evidence does not independently establish the identity, quality or equivalence of a material merely described as “liraglutide peptide.” The purity-versus-content guide explains another reason to keep analytical measurements distinct. A concentration calculation is not a pharmaceutical-equivalence assessment.
How to compare liraglutide with another peptide
When reading reports about liraglutide, semaglutide or tirzepatide, identify the actual comparison before comparing headlines. Look for the study population, assigned intervention, background care, follow-up period, endpoint definition, adverse events and discontinuations.
The research-paper reading guide turns those questions into a practical reading sequence. Neither molecular identity nor a trial average selects an intervention for an individual. This dossier provides no dosing, preparation or administration instructions.
